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Abstract: Uterine myomas or fibroids represent the most common pathology in female genital tract. There are marked 
differences by race in both prevalence and incidence. Pathogenesis of fibroids is still unclear. Several risk factors have 
been identified, ranging from genetic predisposition to variable lifestyles, with recurrence in positive family history for 
fibroids. Although most of them are asymptomatic, they may cause abnormal uterine bleeding and pelvic pain, and are 
associated with several pregnancy-related complications, spontaneous abortion, preterm delivery, and cesarean 
delivery. Moreover, fibroids are associated with several adverse reproductive outcomes and in 10% of infertility case. 
These fibroids related problems can negatively impact daily living and quality of life. Frequently, the diagnosis is 
incidental and the treatment is based on symptoms and patient’ wishes, depending on age, numbers and fibroid’ size, 
woman's fertility plans and risk of malignancy. Because of the high estimated prevalence and costs associated with 
treatments, the direct and indirect costs of uterine fibroids are substantial. This manuscript reviews the current literature 
on uterine fibroids, focusing on updated researches on fibroid management in asymptomatic women. Unfortunately, from 
the data examined, there is no univocity of diagnosis and treatment, thus, further large studies are need to define the 
management of asymptomatic fibroids. 
Keywords: Uterine fibroids, Myoma, Leiomyosarcoma, Reproductive outcomes, Infertility, pregnancy-related 
complications, Spontaneous abortion, Preterm delivery, Cesarean delivery. 
INTRODUCTION 
Uterine fibroids represent the most common 
pathology in female genital tract. Although most of 
them are asymptomatic, they may cause abnormal 
uterine bleeding and pelvic pain. There are few data 
about real incidence of fibroids, because 40-60% of 
them are asymptomatic and are found incidentally in 
course of routine gynecological examination, pelvic 
imaging or during other procedures [1]. Generally, 
fibroids are largely asymptomatic, but they can become 
symptomatic and, despite their relative frequency, the 
pathogenesis and the clinical evolution are still poorly 
understood. Fibroids are well circumscribed, firm, grey-
white and with a whorled cut surface (Figure 1). They 
may degenerate, especially in pregnancy, and become 
soft with a yellowish hue in necrosis or a reddish color 
(Figure 2), due to hemorrhaging [2]. Nevertheless, 
guidelines do not clarify univocally on management and 
on widely accepted indications in asymptomatic 
patients. Here, the aim of this manuscript is to evaluate 
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Figure 1: Fibroids are well circumscribed, firm, grey-white 
and with a whorled cut surface. 
 
Figure 2: Fibroid in pregnancy removed during cesarean 
section. 
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METHODS 
This review was conducted examining more 
common scientific database, as PubMed (MEDLINE), 
Web of Science databases, EMBASE, Cochrane 
Library and Scopus. These databases have been 
investigated for asymptomatic fibroids, in the last 10 
years, searching papers in English-language, 
evaluating epidemiology, biology and management of 
asymptomatic fibroids. Included keywords for the 
search were “Uterine fibroids, myoma, 
leiomyosarcoma, clinical diagnosis, treatment and 
management”. All reports were analyzed and evaluated 
for data. Investigations, whose full manuscript or 
baseline characteristics were not available and those 
not written in English language were excluded from this 
investigation. Final data were included in the 
manuscript. 
HISTOLOGY AND BIOLOGY OF FIBROIDS 
In 65-70% of cases leiomyomata are multiple and 
can be found in various locations most frequently within 
the wall of the uterus (Figure 3) where they can expand 
in the myometrium (Intramural leiomyoma), beneath 
the endometrium (Figure 4), simulating a polyp 
(submucosal leiomyoma), beneath the serosal surface 
(subserosal leiomyoma) (Figure 5), within the broad 
ligament, simulating an adnexal neoplasia 
(infraligamentous leiomyoma) or at the isthmus (Figure 
6) or the myometrium of the neck (cervical leiomyoma). 
The compression of the endometrium causes atrophy 
and erosion with bleeding. Subserosal fibroids can be 
pedunculated (Figure 7) and, in some cases, can 
separate from the uterus and create a new vascular 
peduncle with another nearby organ (parasitic 
leiomyoma) [2]. 
 
Figure 4: Hysteroscopic image of submucous G1 fibroid. 
 
Figure 5: Subserosal fibroid. 
 
Figure 6: Isthmic fibroid. 
 
Figure 3: Laparotomic myomectomy showing many fibroids 
scattered in the context of the uterus. 
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Figure 7: Pedunculated fibroid. 
The fibroids’ biology is still controversial and this 
makes the prediction of possible symptom of the 
fibroma very difficult. Histologically, the tumor is made 
up of cells similar to that of the contiguous 
endometrium (elongated, eosinophilic cytoplasm with 
central, blunt-ended, pale elongated nucleus, 
sometimes with clumped chromatin. The cells form 
whirling fascicles interlaced at right angles. This 
arrangement clearly distinguishes the leiomyoma from 
the surrounding myometrium, which shows a more 
regular pattern of the muscle fibers. Furthermore, a 
large number of tumors show a clear border with the 
myometrium (Figure 8), even forming a valley, 
exaggerated by fixation artefact, with the formation of a 
ring of compressed myometrial cells [2]. 
 
Figure 8: Hysteroscopic image that demonstrates the 
present space between myoma and myometrium (the 
cleavage plane). 
Histopathological analysis revealed that they are 
usually surrounded by a fibro-neuro-vascular 
pseudocapsule (Figure 9), as neurovascular bundle, 
rich of neuropeptides and neurofibers. This 
neurofibrovascular structure of few millimeters 
separates the myometrium from the fibroid (Figure 10) 
and allows the enucleation of the myoma in an 
atraumatic manner and the subsequent activation of 
the muscular regeneration processes [3]. 
 
Figure 9: The laparoscopic enhancement, during 
myomectomy, of the fibro-neuro-vascular pseudocapsule, as 
a neurovascular bundle surrounding fibroid. 
 
Figure 10: The pseudocapsule is neurofibrovascular 
structure of few millimeters separating the myometrium from 
the fibroid. 
Fibroids’ microscopic analysis revealed the 
presence of dense cellular bundles, with a medium 
mitotic activity of 0.8±0.3 mitotic figures (MF) per 
10×microscopic field (10 HPF) without cellular atypia 
[4]. On the contrary, in case of atypical fibroids, 
histologic slides show cells with bizarre polylobulated 
and hyperchromic nuclei, with moderate/severe atypia 
and medium mitotic activity accounting for 1.2±0.3 
MF/10 HPF [4]. The leiomyosarcoma histological 
analysis usually show cells with moderate/severe 
atypia and high mitotic activity (13.2±3.4 MF/HPF 10), 
with hemorrhagic and necrotic areas [4]. 
Generally, fibroids are sensitive to circulating 
estrogens, which will either cause them to grow or to 
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maintain their size. A study on 262 fibroids in 72 
premenopausal women analyzed by magnetic 
resonance imaging (MRI), performed by Peddada et 
al., tracked fibroids’ growth and reporting these 
conclusions: 1) the median fibroids growth rate is 9% 
per 6 months and it declines with age (p<0.05);2) 
single fibroids shows rapid growth more than multiple 
fibroids (p<0.06), maybe for the less competition for 
uterine blood supply; 3) a small percentage of fibroids 
(7%) should demonstrate a spontaneous regression 
also in pre-menopausal women with regular menses 
(more than 20% of size in 6 months); 4) many of the 
shrinking fibroids show loss of arterial blood flow and 
necrosis (it could suggest that vascular events may be 
involved in shrinking, rather than hormonal changes); 
5) different fibroids within the same woman present 
different growth rates (p<0.001) [5]. 
On the contrary, Mavrelos et al. [6] concluded that 
fibroids’ size at the initial diagnosis is a significant 
independent predictor for subsequent fibroids growth 
(p=0.01). In this investigation [6], fibroids measuring 
less than 20 mm and more than 50 mm in diameter at 
initial US analysis show a growth rate up to three times 
higher than fibroids ranging 20-50 mm. Thus, Mavrelos 
et al. concluded that the fibroids’ growth is unilinear: 
they initially start to grow quickly, then they slow down 
growth until the fibroid reaches a certain size, to 
resume a more rapid growth. This is independently 
from their position in the uterus [6]. The median fibroids 
growth rate of his study, on the contrary of the growth 
rates reported by Peddada et al. [5], was 35.2% at one 
year, with a spontaneous regression rate of 21.3%. In 
addition, Baird et al. [7] investigated the fibroids growth 
in 101 fibroids from 36 women, measured at enrolment, 
3, 6, and 12 months by MRI, resulting in three interval-
specific growth rates. They observed growth spurts in 
37 (40%) lesions, with larger fibroids having less short-
term changes than smaller one, concluding that short 
spurts of growth are common for fibroids, suggesting 
that tumor biology may change quickly. 
FIBROIDS AND INFERTILITY 
Fibroids are currently reported as cause of infertility; 
literature shows fibroid in approximately 5-10% of 
infertile patients and are the only cause in 1-2.4% of 
patients affected [8].  
Different theories have been proposed to explain 
the effects of fibroids on fertility, but the mechanisms 
involved are not clear. It is generally accepted that the 
anatomical location of a fibroid as a submucous fibroid 
may impair fertility, but about the influence of intramural 
and subserosal fibroids in causing infertility no 
consensus has ever been achieved. Fibroids may 
distort the uterine cavity making it enlarged, elongated 
and altering its contour and surface area (Figure 11). 
Intramural fibroids may cause dysfunctional uterine 
contractility (Figure 12) which may interfere with sperm 
migration, ovum transport or nidation. Fibroids may 
also be associated with implantation failure or gestation 
discontinuation due to focal endometrial vascular 
disturbance, endometrial inflammation, secretion of 
vasoactive substances or an enhanced endometrial 
androgen environment [9]. 
 
Figure 11: An ultrasonographic 3D scan showing fundal 
submucosal fibroids distorting the uterine cavity. 
 
Figure 12: An ultrasonographic 3D scan showing an 
intramural fundal fibroid. 
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Pritts et al. investigated the impact of fibroids on 
fertility and of myomectomy in improving outcomes, 
showing that patients with submucosal fibroids have a 
relative risk (RR) of 0.36 of achieving clinical 
pregnancy, 0.28 of implantation rate and a RR of 0.32 
of having a live birth when compared to controls 
without fibroids [10]. Basing on such data, clinicians 
usually advise patients to remove submucosal fibroids 
for prevention of subfertility, miscarriage and later 
pregnancy complications. On the contrary, the effect of 
intramural fibroids on infertility is more controversial, 
while subserosal (Figure 13) and pedunculated fibroids 
(Figure 14) have no impact on fertility and they are 
unlikely to cause adverse fertility outcomes [11]. 
 
Figure 13: A laparoscopic image showing a posterior 
subserosal fibroid of the uterine body. 
 
Figure 14: A laparoscopic image showing a posterior 
pedunculated fibroid of the uterine body. 
Oliveira et al. [12] investigated on fertility and 
fibroids’ size, evaluating patients with intramural 
fibroids: if they were greater than 4 cm, they show a 
significantly (p=0.025) lower pregnancy rate than those 
with fibroids ≤4 cm (29% vs 51 % respectively). 
FIBROIDS’ IMPACT ON OBSTETRICAL OUTCOMES 
Fibroids in pregnancy (Figure 15) are linked to an 
increased risk of obstetrical problems, as fetal mal-
presentation, placenta previa (Figure 16), premature 
rupture of membranes, preterm birth, miscarriage, 
postpartum hemorrhage, cesarean section (CS) 
complications. Miscarriage and preterm birth are the 
most commonly reported pregnancy complications in 
pregnants with fibroids.  
 
Figure 15: An ultrasonographic transvaginal scan image 
showing a posterior subserosal fibroid at 10 weeks of 
pregnancy. 
 
Figure 16: An ultrasonographic transvaginal scan image 
showing a placenta previa at 28 weeks of pregnancy. 
About preterm delivery, Klatsky et al. [13] reported 
the rate of preterm delivery in these patients is 16%, 
whereas Lai et al. [14] reported, always such 
pregnants, an increased risk at gestational age <34 
weeks (OR 1.7), <32 weeks (OR 1.9), and <28 weeks 
(OR 2.0). Conti et al. [15], in a multicenter 
observational retrospective study, reported 15.25% 
cases pregnants with fibroids VS 4% in the health 
cases (p<0.0001). About delivery timing, Shavel et al. 
[16] investigated patients with fibroids compared to a 
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control group with no fibroids or small fibroids (<5 cm) 
and demonstrated those with large myomas (>5 cm) 
delivered at a significantly earlier gestational age. 
About miscarriage risk in pregnants with fibroids, 
Klatsky et al. [13] reported an increased risk of 15.3% 
vs 7.7% of control group (OR 1.34) for intramural 
fibroids and 46.7% vs 21.9% for submucosal ones (OR 
3.85) [23], whereas Pritts et al. [10], in their meta-
analysis, on 23 studies of women submitted to assisted 
reproductive technology (ART), confirmed that any 
location of a fibroid was associated with an increased 
risk of miscarriages (OR 1.7) versus patients without 
fibroids, and this two-fold increased risk was furtherly 
confirmed by other studies [13, 14, 17-20]. 
About the risk of placenta previa in pregnants with 
fibroids (Figure 17), two studies reported an 
approximately twofold increased risk [21, 22], while the 
risk of abruptio placentae associated with fibroids was 
reported in three studies [13, 21, 22], with an estimated 
the frequency of placental abruption of 3.0% 
(115/4159) in patients with fibroids vs 0.9% in control 
patients (517/60,474) (p=0.001). 
 
Figure 17: An ultrasonographic transvaginal scan image 
showing a placenta previa at 31 weeks of pregnancy. 
About abnormal fetal presentation, Klatsky et al. 
[13] reported an increased rate in pregnants with 
fibroids, with a cumulative rate of 13% in patients with 
fibroids versus 4.5% in control group, whereas Stout et 
al. [17], the percentage was substantially lower, but 
higher than in control group, with 5.3% compared to 
3.1% (p=0.01) and Navid et al. [22] found breech 
presentation in 12.5%of pregnants. 
About association of fibroids and CS delivery, 
Klatsky et al. [13], reported a high percentage of CS in 
pregnants with fibroids, till 48.8% versus 13.3% of 
those without fibroids, confirmed also by Stout et al. 
[17], whose reported a CS rate of33.1% vs 24.2 1%, 
even after excluding diagnoses of placenta previa and 
breech presentation. Michels et al. [23] evaluated 2.635 
deliveries, reporting a 27% increase risk of CS 
compared with those without myomas (RR, 1.27), so as 
reported the study of Ciavattini et al. [19], although the 
increased risk was limited to women with multiple 
fibroids. 
About the post-partum hemorrhage, Klatsky et al. 
[13] reported a rate of 2.5% in women with fibroids and 
1.4% in those without (p=0.001), whereas Conti et al. 
[15] showed a significant postpartum bleeding in 11,4% 
of cases versus 3,2 % of control group (p < 0.001). 
FIBROIDS TREATMENT IN ASYMPTOMATIC 
WOMEN 
Fibroids are preferentially treated by surgery, as for 
myomectomy; their enucleation is linked to vaginal, 
abdominal or hysteroscopic approach, depending on 
location, number and size. In infertile women, 
submucosal fibroids are usually managed 
hysteroscopically in single time (Figure 18), if fibroid 
size is < 5 cm, but larger fibroids often need repeated 
procedures [24]. There is no univocity in agreeing on 
the advantage of hysteroscopic myomectomy in 
increasing pregnancy rate [25]. 
 
Figure 18: An hysteroscopic image showing a submucosal 
fibroids removal by electric cutting loop. 
Patients who undergo myomectomy for submucosal 
fibroids have been shown to have higher clinical 
pregnancy rates, with a RR of 2.03 compared to 
women with fibroids in situ who did not undergo 
myomectomy (p= 0.028) [26-29].  
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The issue of removing intramural myomas with a 
positive impact on female reproduction is very 
controversial; reports of improved fertility following 
myomectomy for intramural lesions were published 
[30], with these conclusions: submucosal fibroids with 
an intracavitary component impair fertility and 
hysteroscopic excision could be of benefit improving 
pregnancy rates; removal of intramural fibroids >5 cm 
by laparoscopic or laparotomic myomectomy improves 
fertility; surgical management of subserosal fibroids is 
not required to restore fertility. 
A recent consensus [31] on management of 
asymptomatic submucous fibroids in women in 
reproductive age, proposed the following management:  
1. The use of transvaginal ultrasound to document 
the number, size and location of the submucous 
myomas; with subsequent in-office hysteroscopy 
considering, when feasible, a see-and-treat 
approach. 
2. When immediate fertility is not entertained and in 
the presence of one or more asymptomatic 
submucous myomas smaller than 15 mm, 
hysteroscopic myomectomy is recommended but 
expectant management is acceptable. If 
expectant management is favored, clinical 
surveillance of symptoms and serial transvaginal 
pelvic ultrasound to monitor myoma’s growth are 
recommended.  
3. When immediate fertility is a priority and in the 
presence of one or more asymptomatic 
submucous myomas ≥15 mm, hysteroscopic 
myomectomy is recommended.  
4. Among the different available hysteroscopic 
techniques, the cold loop resectoscopic 
myomectomy (Figure 19) should be the favored 
approach, allowing to preserve as much healthy 
myometrium as possible; other hysteroscopic 
myomectomy techniques such as dissection, 
vaporization, or morcellation by Hysteroscopic 
Tissue Removal systems (HTRs) are acceptable. 
Finally, the use of 16 Fr mini-resectoscope, 
when available, should be considered. 
5. The use of both, bipolar or monopolar energy 
devices for hysteroscopic myomectomy, is 
equally acceptable. Always keeping an accurate 
monitoring of the fluid balance regardless of the 
type of distention media used, especially in case 
of prolonged procedures and in patients with 
comorbidities with a known impact on fluid 
hemodynamics such as heart, lung or kidney 
disease.  
6. The use of hysteroscopic laser energy for 
enucleation of submucous myomas is a 
promising therapeutic option, which needs 
further investigation.  
7. Type 0 and type 1 submucous myomas are more 
likely to be completely removed in one-step 
approach; conversely, type 2 submucous 
myomas could require a multi-staged procedure. 
Moreover, the endoscopist may consider 
performing the Office Preparation of Partially 
Intramural Myomas (OPPIuM) technique, which 
consist of making an incision of the endometrial 
mucosa covering the myoma using 
hysteroscopic scissors or bipolar electrode, 
along its reflection line on the uterine wall, up to 
the identification of the cleavage surface 
between the myoma and its pseudocapsule. In 
case of intracavitary myomas ≤40 mm, the 
subsequent second-step excision can also be 
safely performed in office-based setting four 
weeks later. Conversely, for intracavitary 
myomas >40 mm, a second-step resectoscopic 
procedure is recommended. 
8. Suppressive medical therapy aiming to cause 
endometrial hypotrophy and reduction of 
submucous myoma volume may be considered 
before hysteroscopic myomectomy for 
submucous myomas ≥15 mm. However, 
available data is insufficient to identify the best 
pharmacologic strategy.  
9. Cervical priming is recommended to facilitate 
dilation before hysteroscopic myomectomy of 
submucous myomas larger than 15 mm, 
especially in nulliparous women. However, 
available data is insufficient to identify the best 
strategy to prime the cervix. 
10. The use of prophylactic antibiotic administration 
before hysteroscopy in office setting and 
resectoscopic myomectomy in the operating 
room is not recommended, except in case of 
resectoscopic surgery in women with history of 
pelvic inflammatory disease. 
11. Although the risk of intrauterine adhesion 
formation after resectoscopic myomectomy is 
low, it should be minimized by using the cold 
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loop enucleation technique, cognitive use of 
energy on pure “cut” setting minimizing thermal 
spread, and the use of anti-adhesion therapy. 
12. A “second-look’’ hysteroscopy should be 
performed within 3 months of a resectoscopic 
myomectomy to evaluate the uterine cavity and 
early treatment of possible intrauterine adhesion 
formation. 
 
Figure 19: The cold loop resectoscopic myomectomy. 
FIBROIDS AND RISK OF MALIGNANCY 
Generally, fibroids do not arise from uterine 
myomas as a biological progression, excepting rare 
cellular or atypical variants, and from the data so far 
collected, it is unsure if fibroids have a genetic origin. In 
fact, it is still not well understood the biological origin of 
fibroids. The debate is focused on the possibility of 
sudden growing up of fibroids from uterine muscle cells 
or if there is a “sarcomatous degeneration” by a 
karyotypic evolution of fibroids from a benign myoma. 
Literature therefore stated, after a genetic consensus, 
that most leiomyosarcoma (LMS) arise independently 
[32].  
The LMS is a rare aggressive tumor diagnosed 
usually after menopause, around 60 years of age, very 
aggressive and with a poor prognosis too in early-
stage, due to an early hematogenous spread. The 
likelihood ratio of finding an LMS in a female population 
presenting a uterine mass is approximately 0.1 to 
0.28% and it accounts for 2-5% of uterine malignancies 
[33].  
Symptoms may be vague and include uterine 
bleeding, abdominal girth, pelvic pain or pressure [34]. 
The fast growth of intrauterine mass during one year 
should be considered a potential LMS, but it is not 
sufficient to differentiate the diagnosis from other 
uterine enlarging masses. The increased LMS risk was 
not considered in a large, since rapid growth generally 
is in a benign myoma and in an LMS, and no open 
aggressive treatment is warranted to avert the 
presence, “a priori”, of a malignant tumor [35,36]. 
Postmenopausal women in estrogen replacement 
therapy (ERT) have either a lower risk of LMS or a 
small increase of myoma already present prior to ERT 
[37]. 
There are no diagnostic radiologic or 
ultrasonographic (US) tests, that can really distinguish 
benign myomas from LMS.  
Besal et al. evaluated endometrial biopsy or 
curettage in LMS diagnosis [38]. They reported a 
sensitivity of 86% and a specificity of 67%. Currently, 
the diagnosis of ULMS is only by histology after a 
myomectomy or a hysterectomy for presumed 
myomas. Pelvic US is typically the routinely exam to 
investigate uterus with myomas. The US evaluation of 
a uterine mass could identify features compatible with 
LMS diagnosis, such as poor echogenic parts, mixed 
echogenic, central necrosis, irregular vessel distribution 
on color Doppler, high peak systolic velocity and low 
impedance to flow. Unfortunately, these characteristics 
are also present in benign myomas [39]. 
Exacoustos et al. evaluated 257 patients by the 
preoperative gray scale and color Doppler sonographic 
findings, including 225 leiomyomas and 8 LMS. US 
markers significantly associated with LMS presence 
were: lesion diameter > 8 cm, solitary lesion, presence 
of cystic degeneration and increased peripheral and 
central vascularity. A combination of these findings 
leads to a sensitivity rate of 100% and specificity of 
86% [40]. 
Magnetic Resonance Imaging (MRI) is a suggested 
examination in difficult cases where the diagnosis of 
suspect LMS is not clear. Unfortunately, the MRI 
cannot provide a final diagnosis of LMS, since the 
absence of ill-defined margins and calcifications [41] 
and a high signal intensity are not significantly 
associated to LMS [42]. Only two small investigations 
on LMS by gadolinium contrast and MRI slides on 40-
60 seconds after injection, reported positive predictive 
values of 53 to 100% and specificities of 93 to 100% 
[43, 44]. Also computed tomography (CT) failed in the 
differential diagnosis between LMS and myomas [45]. 
The proposed methods to investigate, in 
preoperative time, the myoma characteristics were: 1) 
Dynamic MRI with serum measurement of lactate 
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dehydrogenase (LDH-3) levels; 2) the F-
fluorodeoxyglucose (FDG) CT/Positron Emission 
Tomography (PET). The CT/PET by FDG did not 
provide brilliant results in the differential diagnosis 
between LMS and myomas, since the FDG uptake 
changes in cancers [46]. 
LMS diagnosis can be achieved with certain only 
with the histological analysis of the entire surgical 
specimen; also, frozen section analysis provided poor 
diagnostic results, because the cancer can be present 
only in a small part of the uterine mass and analysis 
typically depends upon a limited tissue sample [46, 47].  
While, at MRI evaluation factors significantly 
associated with LMS included single and large tumor, 
non-myometrial origin, poorly defined margins, 
thickened endometrium, peritoneal implants, 
intermediate or high signal intensity in T1 or T2 
sequences, heterogeneous T1 signal, cystic alteration 
of the tumor and heterogeneity of the tumor’s 
enhancement (p< 0.05) [47]. 
In fact, in case of definitive histologic LMS 
diagnosis, there is a high likelihood of false negative 
results in frozen section analysis [48,49]; thus, only the 
final histology of LMS should influence successive 
surgery [50]. 
FIBROIDS, SERUM MARKERS AND PREDICTION 
OF MALIGNANCY 
Current literature does not report any specific serum 
markers helpful to differentiate between uterine fibroids 
and sarcomas are available [51]. Patsner et al., in 
1988, reported a possible correlation between 
preoperative serum CA125 levels and LMS spread 
[52]. They evaluated 27 women affected by LMS (24 
with primary disease and 3 with recurrence) and found 
that 21.4% of these, in surgical stage I-II and 80%in 
surgical stage III-IV, had an elevated serum CA125 
value. Duk et al. [53] successively confirmed these 
results, evaluating thirty patients diagnosed for LMS: 
40% had elevated serum CA125 levels before 
treatment. The CA125 high serum levels was 
correlated with extrauterine disease (67% of patients 
with elevated serum CA125 had extrauterine tumor 
spread versus 33% with normal serum CA125) and 
with negative prognosis. Recently, other authors 
confirmed these data [54, 55], however the populations 
involved are really small [56]. 
Other researchers have sought to identify other 
biological factors to be investigated as markers of LMS. 
Kim et al. [57] compared serum CA125with 
Neutrophil Lymphocyte ratio (NLR) value, as 
preoperative diagnostic markers for LMS. They showed 
that an NLR ≥2.12 had 74.5% sensitivity and 70.3% 
specificity for the preoperative diagnosis of LMS, 
whereas serum CA125 ≥ 27.5 U/mL had 52.3% 
sensitivity and 50.5% specificity.  
Cho et al. [58] reviewed, retrospectively, 31 women 
affected by LMS and compared, by multivariate 
analysis, them with 93 patients with fibroids. They 
resulted a reporting BMI ≤ 20, NLR > 2.1 and largest-
lesion diameter > 8 cm as independent preoperative 
predictive factors of LMS, with a sensitivity and 
specificity ranging between 41-63.6% for BMI, 78.8-
82.8% for NLR and 41.0% and 82.4% for largest lesion, 
respectively.  
Nevertheless, the serum lactate dehydrogenase 
(LDH), an enzyme elevated in case of tissue necrosis, 
was evaluated in patients diagnosed for LMS; in fact, 
Seki K et al. [59] showed an LDH increase in patients 
affected by LMS. Recently, tumor markers used, to 
evaluate biological seral levels in LMS patients, were 
total LDH and its isozymes, reporting total LDH and 
LDH3 as the best negative predictive value for LMS 
(respectively 100 % and 99.2%) [43].  
Nagai et al. [60] applied to 63 patients, suspected 
for LMS, the PRE-operative Sarcoma Score (PRESS): 
This score included the LDH evaluation and consisted 
of a maximum total of 7 points (1 point for positive MRI 
findings and 2 points each for age, serum LDH values, 
and cytological findings). In the screened population, 
15 patients had a malignant disease. In their analysis, 
the difference between two groups was statistically 
significant for LDH and MRI findings, but not for 
CA125. The sensitivity and specificity of PRESS score 
resulted 73% and 100% respectively for a value up to 
4. 
ASYMPTOMATIC FIBROIDS MANAGEMENT 
Basing on current literature, an annual clinical and 
US follow-up (Figure 20) seems to be sufficient until 
menopause. In post-menopausal period, fibroids 
generally stop growing and are highly unlikely to 
become symptomatic.  
Fibroids should be adequately investigated in case 
of symptoms and if they correlate to a suspicion of 
malignancy, when fibroids size becomes difficult to 
investigate by ultrasound and MRI. 
Uterine Fibroids Management In Asymptomatic Women International Journal of Gynecology, Obstetrics and Neonatal Care, 2019, Vol. 6, No. 1    13 
 
Figure 20: An ultrasonographic transvaginal scan image 
showing a fundal subserosal fibroid. 
About the possible surgical approach to propose in 
patients with fibroids, it should be always including: the 
fibroids’ growth, the fibroids size, any suspicion of 
malignancy, the US imaging, infertility and woman’s 
fertility plans. All reported evidences suggest that the 
fibroid presence, in particular large or multiple lesions, 
has been associated with an increased risk of infertility 
and, in case of pregnancy, with a significant enlarged 
risk of miscarriage, fetal malpresentation, placenta 
previa, preterm birth, cesarean section and postpartum 
hemorrhage. However, controversies about the most 
accurate parameters to exclude malignancy at imaging 
technique still exist and no definitive imaging predicting 
features of malignancy for uterine fibroids have been 
defined. Nonetheless, the combined presence of the 
above-mentioned parameters and fast growing fibroids 
should be of alert and should induce to consider 
surgery.  
Moreover, due to the clinical symptoms, treatment is 
required in approximately a third of patientswith uterine 
fibroids [61] 
About minimally invasive treatments proposed for 
fibroids’ management there are two options: the 
transcervical radiofrequency ablation of fibroids and 
uterine artery embolization (UAE) for fibroid treatment. 
The first option is based on the Sonata System 
(previously called VizAblate), providing transcervical 
radiofrequency ablation. It has been shown, through 
the results of the FAST-EU Trial, to reduce leiomyoma 
volume, decrease heavy menstrual bleeding, and 
improve health utility scores in women with 
symptomatic leiomyomas [62-64]. Another recent 
article described results through 12 months of the 
Sonography Guided Transcervical Ablation of Uterine 
Fibroids pivotal trial [65] performed on 1-10 
leiomyomas per patient with leiomyoma diameters 
ranging from 1 to 5 cm. Coprimary endpoints assessed 
at 12 months were reduction in menstrual blood loss 
and absence of surgical reintervention. Additional 
assessments included symptom severity, quality of life, 
patient satisfaction, reductions in uterine and 
leiomyoma volumes, and safety. Transcervical ablation 
[65] was associated with a significant reduction in 
leiomyoma symptoms with no device-related adverse 
events and a low surgical re-intervention rate through 
12 months, demonstrating its potential to safely and 
effectively treat all non-pedunculated leiomyoma types 
through a uterus-conserving, incisionless approach. 
The decision to recommend UAE should be made 
by interventional radiologist in collaboration with a 
gynecologist who has already discussed the various 
medical and surgical options with the patient and 
absolute contraindications for UAE include viable 
pregnancy, active infection, allergy to contrast agent 
and suspected uterine, cervical, or adnexal 
malignancy. Several reports have demonstrated the 
safety and efficacy of UAE in fibroids larger than 10 cm 
and the UAE is traditionally performed with moderate 
sedation via a right common femoral artery approach 
with embolization of bilateral uterine artery [66]. More 
recently, trans-radial access (TRA) has gained 
popularity for UAE with the apparent advantage of 
allowing patients to move freely following the procedure 
to assume the most comfortable position. Following 
UAE, a substantial inflammatory process manifests 
resulting in the post-embolization syndrome consisting 
of pain, low-grade fevers, nausea, vomiting, and 
malaise [65].  
The expected outcomes following a UAE include 50 
to 60% fibroid size reduction, 40 to 50% uterine size 
reduction, 88 to 92% reduction of bulk symptoms, 
greater than 90% elimination of abnormal uterine 
bleeding, and 80 to 90% patient satisfaction, and at 3-
year follow-up, the overall reintervention rate among 
patients who underwent UAE was 14.4% [67]. 
Complications following UAE can include a 
permanent amenorrhea (0–3% for women younger 
than 45 years, 20–40% for women older than 45 
years), a prolonged vaginal discharge (2–17%), the 
fibroid expulsion (from 1.7 to 50% of cases), septicemia 
(1–3%), pulmonary embolus (<1%), and nontarget 
embolization (<1%) [67]. Less common complications 
include infection, delayed contrast material reactions, 
14    International Journal of Gynecology, Obstetrics and Neonatal Care, 2019, Vol. 6, No.1 Tinelli Andrea 
urinary tract infection or retention, and nerve or vessel 
injury at the access site, with a risk of hysterectomy in 
less than 1% of patients [67]. 
Pharmacological treatments include oral 
contraceptives, progestins, and the levonorgestrel 
releasing intrauterine systems, but they are used ‘off-
label’	   since not indicated for management of uterine 
fibroids because fibroids are progesterone sensitive. 
Moreover, the levonorgestrel-releasing intrauterine 
system is contraindicated in the case of fibroids that 
distort the uterine cavity.  
GnRH agonists, which trigger a temporary 
biochemical menopause, reducing in the progesterone 
and oestrogen levels and inducing amenorrhea; their 
preoperative administration also leads to a hemoglobin 
increase, a reduction of the size of the fibroids. 
Because of their side-effect profile, with climacteric 
complaints and reduced bone density, however, they 
can only be used over a brief period, 
not for more than 3–6 months at a time, as it has 
side effects (like hot flushes and vaginal dryness) and 
may reduce bone mineral density [68].  
Control of bleeding is achieved faster with newer 
drugs like ulipristal acetate (UPA) than with GnRHa. 
The UPA is the latest anti-progestin studied in large 
clinical trials used to treat moderate to severe 
symptoms of uterine fibroids, is the mostly studied of a 
class of substances, the selective progesterone 
receptormodulators (SPRMs).  
UPA has many pharmacological effects on fibroids, 
endometrium and hypothalamus-pituitary axis. The 
direct action on the fibroma of the UPA is by reducing 
the volume of the fibroma and inhibiting cell 
proliferation and induction of apoptosis, by down 
regulating antiapoptotic factors, antifibrotic activity, and 
reducing or blocking growth factor expression. The 
direct action on the endometrium of the UPA is due to 
the rapid reduction of bleeding and to the benign and 
reversible changes of endometrial tissue as 
progesterone associated endometrial changes (PAEC). 
The action on the hypothalamus-pituitary axis is due to 
the inhibition of the LH peak and the estradiol levels 
are maintained as in the follicular middle phase [69]. 
EMA’s Pharmacovigilance Risk Assessment 
Committee (PRAC) has reviewed the benefits and risks 
with ESMYA (UPA 5 mg, Gedeon Richter, Budapest, 
Hungary), following of serious liver injury, including liver 
failure leading to transplantation. The PRAC has 
concluded that ESMYA may have contributed to the 
development of some cases of serious liver injury. After 
considering all the evidence, the PRAC concluded that 
the medicine must not be used in women with liver 
problems and that certain other patients may start new 
treatment courses provided they have regular liver 
tests [70]. 
WHEN TREAT ASYMPTOMATIC FIBROIDS? 
Treatment of asymptomatic myomas should be 
always indicated in case of symptoms and if the 
symptoms correlate to a suspicion of malignancy, when 
fibroids size becomes so large that scanning with 
ultrasound or MRI cannot define its benignity. 
Moreover, fibroids should be treated to enhance fertility 
rate in women wishing pregnancy and to reduce risk of 
negative outcome in pregnancy. Generally, patients 
with fibroids to be treated with minimally invasive 
surgery or methods, as fibroids’ embolization or the 
Sonography Guided Transcervical Ablation of Uterine 
Fibroids should be referred in secondary centers that 
use these methods with experience and employ these 
methods on large numbers. 
In addition, after fibroids diagnostic scan and 
adequately diagnosed by a specialist, patients could be 
referred to a general practitioner, in case of light 
symptoms, for its eventual pharmacological treatment. 
In any case, a patient with uterine fibroids must 
always be carefully evaluated, with an adequate 
counselling, in order to explain and to discuss with risks 
and benefits of all possible management strategies. 
CONCLUSIONS 
Since fibroids represent the most common benign 
gynecological tumors and about 40-60% of patients 
with fibroids are asymptomatic, approximately 50% of 
women will seek a second opinion and no standard 
guidelines for the management of asymptomatic 
fibroids have been reported. Fibroids treatment is 
tailored for patients depending on: risk of malignancy, 
numbers, size and symptoms of fibroids (Figure 20), 
women age and fertility plans. Authors suggested to 
treat fibroids before they grow more than 5 cm [71] 
(Figure 21) and before the treatment becomes more 
challenging for fertility [33], even if the surgical 
treatment should be always performed in case of 
suspicion of LMS or to prevent complications related to 
fibroids excessive size. In case there are not these 
clinical problems, an observation policy is generally 
recommended till the onset of the menopause.  
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Figure 21: A laparoscopic image showing a large intramural 
fibroid of the uterine body, removed for symptoms. 
 
Figure 22: Laparoscopic myomectomy for a 7 cm of diameter 
intramural fibroid removal. 
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